Phaseline

Companies › AvenCell Therapeutics

AvenCell Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Allo-QuadCAR01-T
Allogeneic CAR-T cell therapy targeting CD19/CD20
CD19, CD20Phase 1Lymphoma Diffuse Large B-cellApr 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07284433Allo-QuadCAR01-TPhase 1Lymphoma Diffuse Large B-cellOncologyApr 2029

Targets

CD19 (1) CD20 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech AstraZeneca Allogene Therapeutics Miltenyi Biomedicine Roche Lyell Immunopharma Amgen Beijing Yongtai Ruike Biotechnology Company

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.